Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Tumour × Nivolumab × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 88 Carcinoma, Non-Small-Cell Lung 78 Carcinoma, Renal Cell 45 Neoplasm Metastasis 36 Colorectal Neoplasms 27 Squamous Cell Carcinoma of Head and Neck 26 Carcinoma, Hepatocellular 26 Lung Neoplasms 25 Neoplasms 20 Hodgkin Disease 19 Urinary Bladder Neoplasms 17 Pancreatic Neoplasms 17 Small Cell Lung Carcinoma 15 Sarcoma 15 Carcinoma, Transitional Cell 15 Breast Neoplasms 15 Stomach Neoplasms 14 Prostatic Neoplasms 14 Brain Neoplasms 14 Multiple Myeloma 12 Esophageal Neoplasms 12 Head and Neck Neoplasms 11 Glioblastoma 11 Recurrence 9 Uterine Cervical Neoplasms 8 Rectal Neoplasms 8 Ovarian Neoplasms 8 Neuroendocrine Tumors 8 Mesothelioma, Malignant 8 Lymphoma 8

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡